Ifeanyi-Chukwu Urama (Clinical Immunology)




Four values define our company and culture


We can only change patient’s lives when we perform at our best together. This happens when we focus on what matters, agree who does what and measure our outcomes.


Breakthroughs start by challenging convention, especially in the face of uncertainty or adversity. This happens when we think big, speak up and are decisive.


We believe that every person deserves to be seen, heard and cared for. This happens when we are inclusive, act with integrity and reduce health care disparities.


We give ourselves to our work, but it also gives to us. We find joy when we take pride, recognize one another and have fun.

Watch for a glimpse into the lives of Pfizer scientists as they work to help end the
​​​​​​​COVID-19 pandemic and reflect on the personal impact of their work.



We’re ready for another 170 years of breakthroughs

But first, a look at where we’ve been as we take a look to our future.

Watch how our history of breakthrough science has led us to this moment.


Approach to ESG

Connecting our purpose, strategy and ESG


Our new approach to ESG helps us to advance on our purpose, drive positive impact relevant to the breakthroughs we aim to deliver, demonstrate the value they bring to patients and other stakeholders and govern our operations and impact on society.

Pfizer has consistently supported and prioritized its ESG-related programs and commitments. 2020 marked an important inflection point when it comes to the role of corporations in society, and I am very proud of the ways in which Pfizer stepped up to lead.”

Dr. Albert Bourla

Chairman and Chief Executive Officer

2020 ESG Highlights
Set 2025 goal of global workforce parity of 47% for women at the VP+ level​​
Committed to a landmark $1.25 billion
​​​​​​Sustainability Bond
Ranked 4th in 2021 Access to Medicine Index (ATMI) among 20 companies
By 2030, we aim to become carbon neutral across our internal operations

A closer look: ESG at Pfizer


Building on our commitment to environmental impact reduction through successful completion of our 2012 – 2020 Greenhouse Gas, waste and water withdrawal reduction goals, we are renewing our commitment to ambitious climate action. Our goal is to become carbon neutral across our internal operations by 2030 and catalyze similar reductions throughout our value chain, as recognized by the Science Based Target Initiative. We further aim to reduce the environmental impact of our medicines throughout the product lifecycle through the development of sustainability criteria to measure our progress.



As the COVID-19 pandemic magnifies disparities for underserved communities, Pfizer is working to address the complex issues we face as a global society and create a healthier, more equitable world for all. Through our partnerships and programs, we are seeking to expand affordable access to our breakthrough medicines and vaccines, particularly among underserved communities. As we look to protect all people from the burden of infectious and other diseases, we are also focused on creating opportunities to advance diversity, equity, and inclusion across our workforce and those with whom we do business.



As we work to meet patient and societal needs, we are committed to acting ethically, thoughtfully and responsibly and continually prioritizing safety and transparency in all that we do.  Our compliance program supports proactive business-led quality and compliance governance built around elements of effective risk management. The Board of Directors is critical to our governance by representing shareholders’ interests and seeking to enhance long-term shareholder value. The Board is composed of a majority of independent Directors, reflecting diversity with respect to gender, age, race, ethnicity, background, professional experience and perspectives. 


Pfizer's ESG Report

Our Environmental, Social and Governance (ESG) report represents a new chapter in Pfizer’s commitment to enhance stakeholder awareness of our priority ESG issues and disclose how our performance on non-financial metrics is contributing to long-term value creation and a sustainable, responsible and patient-centric business model. 

Download the report



Chairman and CEO Albert Bourla reflects on a year of breakthrough innovation at Pfizer

Bold Moves

Science illuminates a path forward for patients across the world


Courage, excellence, equity and joy guide all our endeavors


2020 by the numbers

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories